

**AMENDMENTS TO THE CLAIMS:**

Please cancel claims 1-20 without prejudice.

Please add new claims 34-37.

Please amend claim 31 as follows:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-20 (Cancelled)

21. (Previously presented) A method for identifying an anti-cancer agent that modulates a biological activity of a gene product differentially expressed in a cancerous cell as compared to a normal cell, said method comprising:

contacting a candidate anti-cancer agent with a cell that expresses DKFZp5661133; and

detecting a difference between the biological activity of DKFZp5661133 in the presence and absence of the candidate anti-cancer agent, wherein a difference between the level of biological activity of DKFZp5661133 in the presence and absence of the candidate anti-cancer agent indicates that the candidate anti-cancer agent has anti-cancer activity.

22. (Original) The method of claim 21, wherein said cancerous cell and said normal cell are breast cells.

23. (Previously presented) The method of claim 21, wherein said detecting is by assessing expression of said gene product.

24. (Original) The method of claim 23, wherein expression is assessed by detecting a polynucleotide gene product.

25. (Previously presented) The method of claim 23, wherein expression is assessed by detecting a polypeptide gene product.

26. **(Previously presented)** The method of either of claim 21 or claim 32, wherein said candidate agent is selected from the group consisting of a small molecule, an antibody, an antisense polynucleotide, and an RNAi molecule.

27. **(Previously presented)** The method of claim 21, wherein said biological activity is modulation of a cancerous phenotype.

28. **(Original)** The method of claim 27, wherein said cancerous phenotype is abnormal cellular proliferation.

29. **(Previously presented)** The method of claim 27, wherein said cancerous phenotype is loss of contact inhibition.

Claim 30 **(Cancelled)**

31. **(Currently amended)** The method of either of claim 21 or claim 32 wherein the agent is a DKFZ antisense polynucleotide which inhibits DKFZ gene expression by at least 90% comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:508 and SEQ ID NO:510.

32. **(Previously presented)** A method of screening a candidate agent for anti-cancer activity comprising:

- (a) contacting a cell that expresses DKFZp5661133 with a candidate agent; and
- (b) detecting a difference between the level of expression of DKFZp5661133 in the presence and absence of the candidate agent, wherein a difference between the level of DKFZp5661133 expression in the presence and in the absence of the candidate agent indicates that the candidate agent has anti-cancer activity.

33. **(Previously presented)** The method of claim 32 wherein a difference in expression levels of DKFZp5661133 is detected using a polymerase chain reaction, hybridization, or Western blot.

34. **(Previously presented)** The method of either of claims 21 or 32 wherein the cancer is breast cancer.
35. **(New)** The method of claim 31 wherein the DKFZ antisense polynucleotide comprises a nucleotide sequence comprising at least 12 contiguous nucleotides of SEQ ID NO:513, or complement thereof.
36. **(New)** The method of claim 31 wherein the DKFZ antisense polynucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:508 and SEQ ID NO:510.
37. **(New)** The method of claim 21 wherein the biological activity is selected from the group consisting of cell growth, proliferation and invasiveness.